Skip to main content
Erschienen in: Der Nervenarzt 3/2014

01.03.2014 | CME Zertifizierte Fortbildung

Pharmakologische Langzeitbehandlung schizophrener Erkrankungen

verfasst von: L. Deutschenbaur, M. Lambert, M. Walter, D. Naber, PD Dr. C.G. Huber

Erschienen in: Der Nervenarzt | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Erkrankungen aus dem schizophrenen Formenkreis stellen oft beeinträchtigende psychiatrische Krankheiten dar. Obwohl bei einer Reihe von Patienten Verlaufsformen mit wenigen Krankheitsepisoden und gutem klinischem Ergebnis auftreten, kommt es häufig zu einem chronischen und nachteiligen Krankheitsverlauf. Die Langzeittherapie schließt sich an die pharmakologische und psychosoziale Therapie im Rahmen der Akutbehandlung an und umfasst die postakute Stabilisierungsphase und die Remissionsphase. Die vorliegende Arbeit gibt eine Übersicht über Behandlungsempfehlungen zur Langzeitpharmakotherapie, über den Umgang mit Nebenwirkungen, die Behandlung von Nonresponse und Therapieresistenz und die Mitbehandlung komorbider psychischer Störungen. Des Weiteren gibt sie einen Überblick über evidenzbasierte nichtpharmakologische Behandlungsmöglichkeiten. Für die Langzeittherapie der schizophrenen Erkrankungen wird ein integriertes Behandlungskonzept empfohlen, das evidenzbasierte Pharmakotherapie, psychotherapeutische Interventionen und supportive Therapieverfahren kombiniert. Dabei ist es in Zeiten der finanziellen Restriktion im Gesundheitssystem eine der großen Herausforderungen, den Patienten Zugang zu den empfohlenen Behandlungsmöglichkeiten zu verschaffen.
Literatur
1.
Zurück zum Zitat Mcgrath J, Saha S, Chant D et al (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76PubMedCrossRef Mcgrath J, Saha S, Chant D et al (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67–76PubMedCrossRef
2.
Zurück zum Zitat Statistisches Bundesamt (2008) Gesundheitsausgabenrechnung 2007 Statistisches Bundesamt (2008) Gesundheitsausgabenrechnung 2007
3.
Zurück zum Zitat Gaebel W, Woelwer W (2010) Gesundheitsberichterstattung des Bundes, Heft 50: Schizophrenie. Robert Koch Institut, Berlin Gaebel W, Woelwer W (2010) Gesundheitsberichterstattung des Bundes, Heft 50: Schizophrenie. Robert Koch Institut, Berlin
4.
Zurück zum Zitat Hafner H, Maurer K, An Der Heiden W (2013) Schizophrenia – a disorder in its own right?: Results from 25 years of the ABC study. Nervenarzt 84(9):1096–1103 Hafner H, Maurer K, An Der Heiden W (2013) Schizophrenia – a disorder in its own right?: Results from 25 years of the ABC study. Nervenarzt 84(9):1096–1103
5.
Zurück zum Zitat Huber CG, Naber D, Lambert M (2008) Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. Expert Opin Pharmacother 9:2027–2038PubMedCrossRef Huber CG, Naber D, Lambert M (2008) Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors. Expert Opin Pharmacother 9:2027–2038PubMedCrossRef
6.
Zurück zum Zitat Lambert M, Naber D, Huber CG (2008) Management of incomplete remission and treatment resistance in first-episode psychosis. Expert Opin Pharmacother 9:2039–2051PubMedCrossRef Lambert M, Naber D, Huber CG (2008) Management of incomplete remission and treatment resistance in first-episode psychosis. Expert Opin Pharmacother 9:2039–2051PubMedCrossRef
7.
Zurück zum Zitat Schimmelmann BG, Huber CG, Lambert M et al (2008) Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 42:982–990PubMedCrossRef Schimmelmann BG, Huber CG, Lambert M et al (2008) Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 42:982–990PubMedCrossRef
8.
Zurück zum Zitat Lambert M, Naber D, Schacht A et al (2008) Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand 118:220–229PubMedCrossRef Lambert M, Naber D, Schacht A et al (2008) Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand 118:220–229PubMedCrossRef
9.
Zurück zum Zitat Lambert M, Schimmelmann BG, Schacht A et al (2009) Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years. Schizophr Res 107:165–172PubMedCrossRef Lambert M, Schimmelmann BG, Schacht A et al (2009) Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years. Schizophr Res 107:165–172PubMedCrossRef
10.
Zurück zum Zitat Andreasen NC, Carpenter WT Jr, Kane JM et al (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449PubMedCrossRef Andreasen NC, Carpenter WT Jr, Kane JM et al (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441–449PubMedCrossRef
11.
12.
Zurück zum Zitat Heinrichs DW, Hanlon TE, Carpenter WT Jr (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388–398PubMedCrossRef Heinrichs DW, Hanlon TE, Carpenter WT Jr (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388–398PubMedCrossRef
13.
Zurück zum Zitat Alvarez-Jimenez M, Gleeson JF, Henry LP et al (2012) Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychol Med 42:595–606PubMedCrossRef Alvarez-Jimenez M, Gleeson JF, Henry LP et al (2012) Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychol Med 42:595–606PubMedCrossRef
14.
Zurück zum Zitat Tiihonen J, Wahlbeck K, Lonnqvist J et al (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333:224PubMedCentralPubMedCrossRef Tiihonen J, Wahlbeck K, Lonnqvist J et al (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333:224PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Weiden PJ (2007) Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 68(Suppl 14):14–19CrossRef Weiden PJ (2007) Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 68(Suppl 14):14–19CrossRef
16.
Zurück zum Zitat Lencer R, Harris MSH, Weiden PJ et al (2011) Cognitive behavioral therapy for psychosis and medication adherence: when psychopharamcology is not enough. Hogrefe Publishing Lencer R, Harris MSH, Weiden PJ et al (2011) Cognitive behavioral therapy for psychosis and medication adherence: when psychopharamcology is not enough. Hogrefe Publishing
17.
Zurück zum Zitat Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201PubMed Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201PubMed
18.
Zurück zum Zitat Velligan DI, Weiden PJ, Sajatovic M et al (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70(Suppl 4):1–46, quiz 47–48PubMed Velligan DI, Weiden PJ, Sajatovic M et al (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70(Suppl 4):1–46, quiz 47–48PubMed
19.
Zurück zum Zitat Kreyenbuhl J, Nossel IR, Dixon LB (2009) Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature. Schizophr Bull 35:696–703PubMedCentralPubMedCrossRef Kreyenbuhl J, Nossel IR, Dixon LB (2009) Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature. Schizophr Bull 35:696–703PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Tiihonen J, Haukka J, Taylor M et al (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603–609PubMedCrossRef Tiihonen J, Haukka J, Taylor M et al (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603–609PubMedCrossRef
21.
Zurück zum Zitat Lambert M, Naber D (2009) Pharmakotherapie der Schizophrenie. Thieme, Stuttgart Lambert M, Naber D (2009) Pharmakotherapie der Schizophrenie. Thieme, Stuttgart
22.
Zurück zum Zitat Hasan A, Falkai P, Wobrock T et al (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14:2–44PubMedCrossRef Hasan A, Falkai P, Wobrock T et al (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14:2–44PubMedCrossRef
23.
Zurück zum Zitat Kissling W (1991) The current unsatisfactory state of relapse prevention in schizophrenic psychoses – suggestions for improvement. Clin Neuropharmacol 14(Suppl 2):33–44 Kissling W (1991) The current unsatisfactory state of relapse prevention in schizophrenic psychoses – suggestions for improvement. Clin Neuropharmacol 14(Suppl 2):33–44
24.
Zurück zum Zitat Leucht S, Tardy M, Komossa K et al (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071PubMedCrossRef Leucht S, Tardy M, Komossa K et al (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071PubMedCrossRef
25.
Zurück zum Zitat Benkert O, Hippius H (2013) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin Benkert O, Hippius H (2013) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin
26.
Zurück zum Zitat Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663–667PubMedCrossRef Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663–667PubMedCrossRef
27.
Zurück zum Zitat Gaebel W, Jänner M, Frommann N et al (2002) First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 53:145–159PubMedCrossRef Gaebel W, Jänner M, Frommann N et al (2002) First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 53:145–159PubMedCrossRef
28.
Zurück zum Zitat Emsley R, Oosthuizen PP, Koen L et al (2012) Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 73:e541–e547PubMedCrossRef Emsley R, Oosthuizen PP, Koen L et al (2012) Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry 73:e541–e547PubMedCrossRef
29.
Zurück zum Zitat Gaebel W, Riesbeck M, Wolwer W et al (2011) Relapse prevention in first-episode schizophrenia – maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 72:205–218PubMedCrossRef Gaebel W, Riesbeck M, Wolwer W et al (2011) Relapse prevention in first-episode schizophrenia – maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 72:205–218PubMedCrossRef
30.
Zurück zum Zitat Wunderink L, Nieboer RM, Wiersma D et al (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70:913–920PubMedCrossRef Wunderink L, Nieboer RM, Wiersma D et al (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70:913–920PubMedCrossRef
31.
Zurück zum Zitat Leucht S, Corves C, Arbter D et al (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41PubMedCrossRef Leucht S, Corves C, Arbter D et al (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41PubMedCrossRef
32.
Zurück zum Zitat Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962PubMedCrossRef Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962PubMedCrossRef
33.
Zurück zum Zitat Kjelby E, Jorgensen HA, Kroken RA et al (2011) Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry 11:145PubMedCentralPubMedCrossRef Kjelby E, Jorgensen HA, Kroken RA et al (2011) Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry 11:145PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Lambert M, Schimmelmann BG, Schacht A et al (2011) Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models. J Clin Psychopharmacol 31:226–230PubMedCrossRef Lambert M, Schimmelmann BG, Schacht A et al (2011) Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models. J Clin Psychopharmacol 31:226–230PubMedCrossRef
35.
Zurück zum Zitat Huber CG, Schottle D, Lambert M et al (2012) Brief Psychiatric Rating Scale – Excited Component (BPRS-EC) and neuropsychological dysfunction predict aggression, suicidality, and involuntary treatment in first-episode psychosis. Schizophr Res 134:273–278PubMedCrossRef Huber CG, Schottle D, Lambert M et al (2012) Brief Psychiatric Rating Scale – Excited Component (BPRS-EC) and neuropsychological dysfunction predict aggression, suicidality, and involuntary treatment in first-episode psychosis. Schizophr Res 134:273–278PubMedCrossRef
36.
Zurück zum Zitat Tiihonen J, Lonnqvist J, Wahlbeck K et al (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620–627PubMedCrossRef Tiihonen J, Lonnqvist J, Wahlbeck K et al (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620–627PubMedCrossRef
37.
Zurück zum Zitat Leucht C, Heres S, Kane JM et al (2011) Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127:83–92PubMedCrossRef Leucht C, Heres S, Kane JM et al (2011) Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127:83–92PubMedCrossRef
38.
Zurück zum Zitat Fusar-Poli P, Kempton MJ, Rosenheck RA (2013) Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 28:57–66PubMedCrossRef Fusar-Poli P, Kempton MJ, Rosenheck RA (2013) Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 28:57–66PubMedCrossRef
39.
Zurück zum Zitat Kishimoto T, Nitta M, Borenstein M et al (2013) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74:957–965PubMedCrossRef Kishimoto T, Nitta M, Borenstein M et al (2013) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74:957–965PubMedCrossRef
40.
Zurück zum Zitat Kirson NY, Weiden PJ, Yermakov S et al (2013) Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74:568–575PubMedCrossRef Kirson NY, Weiden PJ, Yermakov S et al (2013) Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 74:568–575PubMedCrossRef
41.
Zurück zum Zitat Gentile S (2013) Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy 33:1087–1106PubMed Gentile S (2013) Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy 33:1087–1106PubMed
42.
Zurück zum Zitat Buchanan RW, Kreyenbuhl J, Kelly DL et al (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71–93PubMedCentralPubMedCrossRef Buchanan RW, Kreyenbuhl J, Kelly DL et al (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71–93PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125:15–24PubMedCrossRef Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125:15–24PubMedCrossRef
44.
Zurück zum Zitat Sommer IE, Begemann MJ, Temmerman A et al (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38:1003–1011PubMedCentralPubMedCrossRef Sommer IE, Begemann MJ, Temmerman A et al (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 38:1003–1011PubMedCentralPubMedCrossRef
45.
Zurück zum Zitat Gaebel W, Falkai P (2005) Behandlungsleitlinie Schizophrenie. Steinkopff, Darmstadt Gaebel W, Falkai P (2005) Behandlungsleitlinie Schizophrenie. Steinkopff, Darmstadt
46.
Zurück zum Zitat Huber CG (2006) Co-morbid psychiatric disorders in schizophrenia. Psychoneuro 32:372–378CrossRef Huber CG (2006) Co-morbid psychiatric disorders in schizophrenia. Psychoneuro 32:372–378CrossRef
47.
Zurück zum Zitat Schroeder K, Hoppe A, Andresen B et al (2012) Considering DSM-5: personality diagnostics in patients with schizophrenia spectrum disorders. Psychiatry 75:120–134PubMed Schroeder K, Hoppe A, Andresen B et al (2012) Considering DSM-5: personality diagnostics in patients with schizophrenia spectrum disorders. Psychiatry 75:120–134PubMed
48.
Zurück zum Zitat Walter M, Denier N, Vogel M et al (2012) Effects of psychoactive substances in schizophrenia – findings of structural and functional neuroimaging. Curr Top Med Chem 12:2426–2433PubMedCrossRef Walter M, Denier N, Vogel M et al (2012) Effects of psychoactive substances in schizophrenia – findings of structural and functional neuroimaging. Curr Top Med Chem 12:2426–2433PubMedCrossRef
49.
Zurück zum Zitat Gouzoulis-Mayfrank E (2013) Psychotische Störungen und komorbide Suchterkrankungen. In: Walter M, Gouzoulis-Mayfrank E (Hrsg) Psychische Störungen und Suchterkrankungen: Diagnostik und Behandlung von Doppeldiagnosen. Kohlhammer, Stuttgart, S 75–87 Gouzoulis-Mayfrank E (2013) Psychotische Störungen und komorbide Suchterkrankungen. In: Walter M, Gouzoulis-Mayfrank E (Hrsg) Psychische Störungen und Suchterkrankungen: Diagnostik und Behandlung von Doppeldiagnosen. Kohlhammer, Stuttgart, S 75–87
50.
Zurück zum Zitat Gouzoulis-Mayfrank E (2007) Komorbidität Psychose und Sucht. Grundlagen und Praxis. Mit Manualen für die Psychoedukation und Verhaltenstherapie. Steinkopff, Darmstadt Gouzoulis-Mayfrank E (2007) Komorbidität Psychose und Sucht. Grundlagen und Praxis. Mit Manualen für die Psychoedukation und Verhaltenstherapie. Steinkopff, Darmstadt
51.
Zurück zum Zitat APA (2004) Practice guideline for the treatment of patients with schizophrenia (second edition). In: American Psychiatric Association (Hrsg) Practice guidelines for the treatment of psychiatric disorders, compendium 2004. American Psychiatric Publishing, Arlington, S 249–440 APA (2004) Practice guideline for the treatment of patients with schizophrenia (second edition). In: American Psychiatric Association (Hrsg) Practice guidelines for the treatment of psychiatric disorders, compendium 2004. American Psychiatric Publishing, Arlington, S 249–440
52.
Zurück zum Zitat Karow A, Reimer J, Konig HH et al (2012) Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 73:e402–e408PubMedCrossRef Karow A, Reimer J, Konig HH et al (2012) Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 73:e402–e408PubMedCrossRef
53.
Zurück zum Zitat Lambert M, Bock T, Schottle D et al (2010) Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 71:1313–1323PubMedCrossRef Lambert M, Bock T, Schottle D et al (2010) Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry 71:1313–1323PubMedCrossRef
54.
Zurück zum Zitat Cook JA, Razzano L (2000) Vocational rehabilitation for persons with schizophrenia: recent research and implications for practice. Schizophr Bull 26:87–103PubMedCrossRef Cook JA, Razzano L (2000) Vocational rehabilitation for persons with schizophrenia: recent research and implications for practice. Schizophr Bull 26:87–103PubMedCrossRef
Metadaten
Titel
Pharmakologische Langzeitbehandlung schizophrener Erkrankungen
verfasst von
L. Deutschenbaur
M. Lambert
M. Walter
D. Naber
PD Dr. C.G. Huber
Publikationsdatum
01.03.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Der Nervenarzt / Ausgabe 3/2014
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-013-3807-7

Weitere Artikel der Ausgabe 3/2014

Der Nervenarzt 3/2014 Zur Ausgabe